Evidence map›Paper›PMID 40460450›Full record

ReviewJournal of radiation research2025

Radiotherapy treatment planning for esophageal cancer: JASTRO guidelines 2024 for radiotherapy treatment planning.

Keiichi Jingu, Keiji Nihei, Yoshinori Ito, Masahiko Okamoto, Hiroshi Doi, Hirofumi Ogawa, Masakatsu Onozawa, Terufumi Kawamoto, Norio Katoh, Atsuya Takeda and 7 more

Abstract readReview
In one paragraph

Review in Journal of radiation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Keiichi JinguDepartment of Radiation Oncology, Tohoku University Graduate School of Medicine, 1-1 Seiryo-chou, Aoba-ku, Sendai, Miyagi, 980-8574, Japan.
Keiji NiheiDepartment of Radiation Oncology, Faculty of Medicine, Osaka Medical and Pharmaceutical University, Osaka, 2-7 Daigakumachi, Takatsuki-shi, Osaka, 569-8686, Japan.
Yoshinori ItoDepartment of Radiation Oncology, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, 142-8666, Japan.
Masahiko OkamotoDepartment of Radiation Oncology, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi-shi, Gunma, 371-8511, Japan.
Hiroshi DoiDepartment of Radiation Oncology, Kindai University Faculty of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama, Osaka, 589-8511, Japan.
Hirofumi OgawaRadiation and Proton Therapy Center, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8777, Japan.
Masakatsu OnozawaDepartment of Radiation Oncology, Funabashi Municipal Medical Center, 1-21-1 Kanasugi, Funabashi-shi, Chiba, 273-8588, Japan.
Terufumi KawamotoDepartment of Radiation Oncology, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8431, Japan.
Norio KatohDepartment of Radiation Oncology, Hokkaido University Faculty of Medicine, N15-W7, Kitaku, Sapporo, Hokkaido, 060-868, Japan.
Atsuya TakedaDepartment of Radiology, Keio University School of Medicine, 35 Shinano, Shinjuku-ku, Tokyo, 160-8582, Japan.
Hirokazu MakishimaQST Hospital, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba, 263-8555, Japan.
Hiroshi MayaharaDivision of Radiation Oncology, Kobe Minimally Invasive Cancer Center, 8-5-1 Minatojima-Nakamachi, Chuou-Ku, Kobe, Hyogo, 650-0046, Japan.
Hideya YamazakiDepartment of Radiology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto, 602-8566, Japan.
Keiko Nemoto MurofushiDivision of Radiation Oncology, Department of Radiology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo, 113-8677, Japan.
Kayoko TsujinoDepartment of Radiation Oncology, Hyogo Cancer Center, 13-70 Kitaojicho, Akashi-shi, Hyogo, 673-0021, Japan.
Hiroshi IgakiDepartment of Radiation Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Takashi UnoDiagnostic Radiology and Radiation Oncology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chou-ku, Chiba, 260-8677, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Japanese Society for Radiation Oncology (JASTRO) Guidelines for Radiotherapy Treatment Planning have been revised every four years to incorporate the latest findings since the publication of the first edition in 2004. This is a review which presents the 2024 JASTRO Guidelines for radiotherapy treatment planning for esophageal cancer in English. Regarding the treatment of esophageal cancer, various new findings have emerged over the past 4 years, leading to significant updates in the 2020 edition, particularly in the following six areas: (i) additional details on indications for superficial cancer, (ii) inclusion of clinical trial results (JCOG1109) for neoadjuvant chemotherapy and chemoradiotherapy in locally advanced cases in Japan, (iii) updated references on prophylactic lymph node irradiation, (iv) updates on IMRT, (v) revisions in accordance with the 5th edition of the Esophageal Cancer Treatment Guidelines, and (vi) additions of FOLFOX to concurrent chemotherapy regimens.

Indexed as

Esophageal NeoplasmsPractice Guidelines as TopicRadiotherapy Planning, Computer-AssistedHumansatlas for elective lymph node areasesophageal cancerguidelines 2024JASTROradiotherapy treatment planning

Identifiers

PMID40460450
PMCPMC12283517

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.